SG10201912216VA - Benzenesulfonamide compounds and their use as therapeutic agents - Google Patents

Benzenesulfonamide compounds and their use as therapeutic agents

Info

Publication number
SG10201912216VA
SG10201912216VA SG10201912216VA SG10201912216VA SG10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA SG 10201912216V A SG10201912216V A SG 10201912216VA
Authority
SG
Singapore
Prior art keywords
therapeutic agents
benzenesulfonamide compounds
benzenesulfonamide
compounds
therapeutic
Prior art date
Application number
SG10201912216VA
Inventor
Jean-Christophe Andrez
Kristen Burford
Sultan Chowdhury
Charles Cohen
Christoph Dehnhardt
Robert Devita
James Empfield
Thilo Focken
Michael Grimwood
Syed Hasan
James Johnson
Alla Zenova
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of SG10201912216VA publication Critical patent/SG10201912216VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201912216VA 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents SG10201912216VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339773P 2016-05-20 2016-05-20
US201662432152P 2016-12-09 2016-12-09

Publications (1)

Publication Number Publication Date
SG10201912216VA true SG10201912216VA (en) 2020-02-27

Family

ID=58794232

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912216VA SG10201912216VA (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents
SG11201809702SA SG11201809702SA (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809702SA SG11201809702SA (en) 2016-05-20 2017-05-19 Benzenesulfonamide compounds and their use as therapeutic agents

Country Status (17)

Country Link
US (4) US10246453B2 (en)
EP (1) EP3458449A1 (en)
JP (3) JP6938545B2 (en)
KR (1) KR102366077B1 (en)
CN (1) CN109526219B (en)
AU (2) AU2017268006B2 (en)
CA (1) CA3023465A1 (en)
CL (1) CL2018003260A1 (en)
CO (1) CO2018012485A2 (en)
IL (1) IL262834B (en)
MX (1) MX2018013985A (en)
PH (1) PH12018502378A1 (en)
RU (1) RU2769827C2 (en)
SG (2) SG10201912216VA (en)
TN (1) TN2018000385A1 (en)
WO (1) WO2017201468A1 (en)
ZA (1) ZA201807518B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109526219B (en) 2016-05-20 2021-03-12 泽农医药公司 Benzenesulfonamides and their use as therapeutic agents
BR112019011121A2 (en) 2016-12-09 2019-10-01 Xenon Pharmaceuticals Inc benzenesulfonamide compounds and their use as therapeutic agents
CN112262142B (en) * 2018-06-13 2023-11-14 泽农医药公司 Benzenesulfonamide compounds and their use as therapeutic agents
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CR20210099A (en) 2018-08-31 2021-06-24 Xenon Pharmaceuticals Inc Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
US20230404913A1 (en) * 2020-10-13 2023-12-21 Xenon Pharmaceuticals, Inc. Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels
WO2022077095A1 (en) * 2020-10-13 2022-04-21 Xenon Pharmaceuticals Inc. Use of the navi.6 sodium channel blocker (s)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-n( thiazol-4-yl)benzenesulfonamide, together with strong inducers of cytochrome p450 3a4, in the treatment of conditions associated with nav1.6 activity
WO2023235734A1 (en) 2022-06-02 2023-12-07 Neurocrine Biosciences, Inc. Deuterated compounds

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
CA2288046C (en) 1997-05-07 2006-10-03 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
DK1202724T3 (en) 1999-07-16 2004-01-26 Warner Lambert Co Method of Treating Chronic Pain Using Mech Inhibitors
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
US8933236B2 (en) * 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
FR2836917B1 (en) 2002-03-11 2006-02-24 Lipha NITROSO DIPHENYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS MEDICAMENTS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY OXIDATIVE STRESS SITUATION
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AU2004255342C1 (en) 2003-07-08 2009-05-14 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006038594A1 (en) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N-type calcium channel inhibitor
JP2008524244A (en) 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド Hydroxyl steroid dehydrogenase inhibitor
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2007039171A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
NZ569694A (en) 2005-12-21 2011-06-30 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
WO2008019967A2 (en) * 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
CN101679432B (en) 2006-10-19 2015-04-22 西格诺药品有限公司 Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
EP2175728B1 (en) 2007-07-13 2014-09-10 Icagen, Inc. Sodium channel inhibitors
WO2009013171A2 (en) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2289868B1 (en) 2008-06-25 2014-08-13 Daiichi Sankyo Company, Limited Carboxylic acid compound
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
BRPI1006128A2 (en) 2009-01-12 2016-11-01 Cagen Inc sulfonamide derivatives
JP5830534B2 (en) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Compound
SG187742A1 (en) 2010-08-20 2013-03-28 Hutchison Medipharma Ltd Pyrrolopyrimidine compounds and uses thereof
MX2014001851A (en) 2011-08-17 2014-10-24 Amgen Inc Heteroaryl sodium channel inhibitors.
CA2852796A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
BR112014010271A2 (en) * 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc benzenesulfonamide compounds and their use as therapeutic agents
EP2773641B1 (en) * 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
MY177422A (en) 2012-10-15 2020-09-15 Dae Woong Pharma Sodium channel blockers, preparation method thereof and use thereof
CN104869992A (en) 2012-10-26 2015-08-26 默沙东公司 N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
RU2015119635A (en) 2012-10-26 2016-12-20 Мерк Шарп И Доум Корп. COMPOUNDS OF BENZOXAZOLINONE WITH SELECTIVE ACTIVITY IN POTENTIAL DEPENDENT SODIUM CHANNELS
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
TW201443025A (en) 2013-04-19 2014-11-16 Pfizer Ltd Chemical compounds
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
JP6407285B2 (en) 2013-09-09 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ RORγ regulator
US20160221974A1 (en) 2013-09-10 2016-08-04 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
CA2931732A1 (en) * 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2015077905A1 (en) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels
CA2934473C (en) 2013-12-23 2019-08-20 Purdue Pharma L.P. Indazoles and use thereof
EP3166939B1 (en) * 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN106795149B (en) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 Double cyclosubstituted benzenesulfonamide derivatives, its preparation method and purposes pharmaceutically
CA3008614A1 (en) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
CN109526219B (en) 2016-05-20 2021-03-12 泽农医药公司 Benzenesulfonamides and their use as therapeutic agents
US10968210B2 (en) 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
BR112019011121A2 (en) 2016-12-09 2019-10-01 Xenon Pharmaceuticals Inc benzenesulfonamide compounds and their use as therapeutic agents
CN112262142B (en) * 2018-06-13 2023-11-14 泽农医药公司 Benzenesulfonamide compounds and their use as therapeutic agents
US10752623B2 (en) 2018-08-31 2020-08-25 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Also Published As

Publication number Publication date
MX2018013985A (en) 2019-08-22
TN2018000385A1 (en) 2020-06-15
AU2021203771A1 (en) 2021-07-08
CN109526219B (en) 2021-03-12
AU2021203771B2 (en) 2022-09-29
PH12018502378A1 (en) 2019-03-11
KR20190007050A (en) 2019-01-21
WO2017201468A1 (en) 2017-11-23
JP2019516737A (en) 2019-06-20
BR112018073849A2 (en) 2019-02-26
CL2018003260A1 (en) 2019-01-11
CN109526219A (en) 2019-03-26
US20190194184A1 (en) 2019-06-27
US20170334902A1 (en) 2017-11-23
JP2021185189A (en) 2021-12-09
US11299490B2 (en) 2022-04-12
JP2023108032A (en) 2023-08-03
CO2018012485A2 (en) 2019-04-30
CA3023465A1 (en) 2017-11-23
JP6938545B2 (en) 2021-09-22
AU2017268006A1 (en) 2018-11-22
SG11201809702SA (en) 2018-12-28
US10815229B1 (en) 2020-10-27
IL262834A (en) 2018-12-31
US10246453B2 (en) 2019-04-02
KR102366077B1 (en) 2022-02-21
EP3458449A1 (en) 2019-03-27
RU2769827C2 (en) 2022-04-06
ZA201807518B (en) 2023-07-26
AU2017268006B2 (en) 2021-03-11
RU2018145045A (en) 2020-06-22
US20200354354A1 (en) 2020-11-12
RU2018145045A3 (en) 2020-06-22
US10662184B2 (en) 2020-05-26
AU2017268006A8 (en) 2018-12-06
IL262834B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
HK1256383A1 (en) Therapeutic agents
GB201709456D0 (en) Therapeutic agents
HK1247614A1 (en) Therapeutic compounds and uses thereof
IL267143A (en) Benzenesulfonamide compounds and their use as therapeutic agents
ZA201807518B (en) Benzenesulfonamide compounds and their use as therapeutic agents
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
GB201603104D0 (en) Therapeutic agents
IL250990A0 (en) Human therapeutic agents
HK1248697A1 (en) Therapeutic compounds and uses thereof
GB201617064D0 (en) Compounds and their therapeutic use
ZA201802256B (en) Compounds and therapeutic uses thereof
IL278949A (en) Benzenesulfonamide compounds and their use as therapeutic agents
GB201608797D0 (en) Therapeutic use
GB201715194D0 (en) Compounds and their therapeutic use
GB201509885D0 (en) Therapeutic agents
GB201509888D0 (en) Therapeutic agents
IL265269B (en) Novel compounds and therapeutic uses thereof
GB201418809D0 (en) Therapeutic agents and uses thereof
GB201700553D0 (en) Therapeutic agents
EP3302530A4 (en) Cdh26 based therapeutic agents and their use
GB201513299D0 (en) Therapeutic agents
GB201700526D0 (en) Therapeutic use
GB201600376D0 (en) Novel therapeutic agents
GB201521767D0 (en) Therapeutic agents